Lupin gets 2 observations from USFDA after Nagpur facility inspection

Topics Lupin Pharma

Drug firm Lupin on Saturday said it has received two observations from the US health regulator following the inspection of its Nagpur manufacturing facility.

A PAI (Prior Approval Inspection) was carried out by the United States Food and Drug Administration (USFDA) at the company's Nagpur oral solid dosage manufacturing facility between January 6-10, 2020, Lupin said in a filing to BSE.

"The inspection closed with two 483 observations," Lupin said.

The USFDA issues observations by means of Form 483 notifying a company's management of objectionable conditions at the facility inspected.

"We are committed to meeting the highest quality standards and are committed to full compliance with CGMP regulations at all our manufacturing facilities. The Nagpur facility is our latest oral solid dosage facility, and this was the seventh USFDA inspection at the facility," Lupin MD Nilesh Gupta said.

Lupin will address the observations raised by the agency satisfactorily and will submit a comprehensive response within the stipulated timeline, he added.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel